Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 29;33(6):1255-1270.
doi: 10.32604/or.2025.062142. eCollection 2025.

Recent advances in understanding the role of sex hormone receptors in urothelial cancer

Affiliations
Review

Recent advances in understanding the role of sex hormone receptors in urothelial cancer

Mohammad Amin Elahi Najafi et al. Oncol Res. .

Abstract

Sex hormones, including androgens and estrogens, are known to have widespread physiological actions beyond the reproductive system via binding to their cognitive receptors, members of the nuclear receptor superfamily that function as ligand-inducible transcription factors. Meanwhile, a growing body of evidence has indicated the involvement of androgen receptor, as well as estrogen receptors such as estrogen receptor-α and estrogen receptor-β, in the pathogenesis and growth of various types of malignancies, including urothelial cancer. Additionally, in bladder cancer, the activity of sex hormone receptors has been implicated in modulating sensitivity to conventional non-surgical therapy. These may clearly explain sex-related differences in the incidence and prognosis of bladder cancer. This article focuses on summarizing the recent progress on understanding the role of sex hormones and their receptors in urothelial tumorigenesis, urothelial cancer progression, and resistance to non-surgical therapy for bladder cancer. Specifically, potential downstream effectors of sex hormone receptors have been newly identified. Thus, most of previous and subsequent data have indicated that activation of the androgen receptor or estrogen receptor-β pathway is favorable for urothelial cancer, while conflicting data exist especially on estrogen receptor-α functions.

Keywords: Androgen receptor; Bladder cancer; Estrogen receptor; Urothelial cancer.

PubMed Disclaimer

Conflict of interest statement

Hiroshi Miyamoto has received research funding from Astellas Scientific and Medical Affairs, Ferring Research Institute, and Bristol Myers Squibb. Other authors declare no conflicts of interest to report.

Figures

Figure 1
Figure 1. Androgen/estrogen-mediated signals, including potential downstream effectors, in non-neoplastic urothelial cells or urothelial cancer cells. Androgens or estrogens have been suggested to modulate tumorigenesis and tumor progression, as well as resistance to conventional non-surgical therapy for bladder cancer, through the ligand-mediated AR, ERα, and/or ERβ pathway(s) via up-regulating/activating (red) or down-regulating/inactivating (blue) the downstream targets listed. A, androgen; ARE, androgen response element; E, estrogen; ERE, estrogen response element; HSP, heat shock protein.

Similar articles

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA A Cancer J Clinicians. 2015;65(2):87–108. doi:10.3322/caac.21262; - DOI - PubMed
    1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. . Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63. doi:10.3322/caac.21834; - DOI - PubMed
    1. SEER Cancer Stat Facts: Bladder Cancer , National Cancer Institute; [accessed 2024 Dec 9]. Available from: http://seer.cancer.gov/statfacts/html/urinb.html.
    1. Goto T, Miyamoto H. Why has the prognosis for muscle-invasive bladder cancer not significantly improved after decades of therapeutic advancements? Expert Rev Anticancer Ther. 2020;20(4):229–31. doi:10.1080/14737140.2020.1744437; - DOI - PubMed
    1. Esteban-Villarrubia J, Torres-Jiménez J, Bueno-Bravo C, García-Mondaray R, Subiela JD, Gajate P. Current and future landscape of perioperative treatment for muscle-invasive bladder cancer. Cancers. 2023;15(3):566. doi:10.3390/cancers15030566; - DOI - PMC - PubMed

LinkOut - more resources